

Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

November 2022

The logo for PHARMAC, featuring the word "PHARMAC" in a bold, uppercase, sans-serif font, with "TE PĀTAKA WHAIORANGA" in a smaller, uppercase, sans-serif font below it. The logo is centered within a white circle that overlaps a background of stylized, wavy, concentric lines in shades of gray and white.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 November 2022.....	3
Section H changes to Part II	5
Index.....	11

Summary of decisions

EFFECTIVE 1 NOVEMBER 2022

- Aciclovir (Lovir) tab dispersible 400 mg and 800 mg – price increase and addition of PSS
- Azathioprine (Azamun) tab 25 mg – price increase and addition of PSS
- Caspofungin (Alchemy Caspofungin) inj 50 mg and 70 mg vial – new listing and addition of PSS
- Caspofungin (Max Health) inj 50 mg and 70 mg vial – to be delisted 1 April 2023
- Cefaclor (Ranbaxy-Cefaclor) cap 250 mg and grans for oral liq 25 mg per ml, 100 ml – price increase and addition of PSS
- Cefalexin (Cephalexin ABM) cap 250 mg – price increase and addition of PSS
- Cefalexin (Cephalexin ABM) cap 500 mg – price decrease and addition of PSS
- Ceftriaxone (Ceftriaxone-AFT) inj 500 mg and 1 g vial – price decrease and addition of PSS
- Chlortalidone [chlorthalidone] (Hygroton) tab 25 mg – price increase and addition of PSS
- Clotrimazole (Clomazol) crm 1%, 20 g, vaginal crm 1% with applicator, 35 g and vaginal crm 2% with applicator, 20 g – price increase and addition of PSS
- Codeine phosphate (Noumed) tab 30 mg and 60 mg – new listing and addition of PSS
- Codeine phosphate (PSM) tab 30 mg and 60 mg – to be delisted 1 April 2023
- Darunavir (Darunavir Viatrix) tab 600 mg – new listing
- Durvalumab (Imfinzi) inj 50 mg per ml, 2.4 ml and 10 ml vial – amended restriction criteria
- High protein oral feed 2.4 kcal/ml (e.g. Fortisip Compact Protein) liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle – delisting delayed
- Hydrocortisone (Ethics) crm 1%, 30 g – new listing and addition of PSS
- Hydrocortisone (Hydrocortisone (PSM)) crm 1%, 100 g – to be delisted 1 April 2023
- Intra-uterine device IUD 29.1 mm length × 23.2 mm width (Choice TT380 Short), IUD 33.6 mm length × 29.9 mm width (Choice TT380 Standard) and IUD 35.5 mm length × 19.6 mm width (Choice Load 375) – price increase and addition of PSS
- Lactulose (Laevolac) oral liq 10 g per 15 ml, 500 ml – price increase and addition of PSS

Summary of decisions – effective 1 November 2022 (continued)

- Levomepromazine hydrochloride (Wockhardt) inj 25 mg per ml, 1 ml ampoule – new listing and addition of PSS
- Levomepromazine hydrochloride (Nozinan) inj 25 mg per ml, 1 ml ampoule – to be delisted 1 April 2023
- Morphine sulphate (m-Eslon) cap long-acting 10 mg, 30 mg, 60 mg and 100 mg – price increase and addition of PSS
- Olaparib (Lynparza) tab 100 mg and 150 mg – amended restriction criteria
- Paediatric enteral feed 1 kcal/ml (e.g. Nutrini RTH) liquid 2.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle – amended presentation description
- Paracetamol (Pamol) oral liq 250 mg per 5 ml, 200 ml – new listing and addition of PSS
- Paracetamol oral liq 250 mg per 5 ml (Paracare Double Strength), oral liq 250 mg per 5 ml – 100 ml, 200 ml and 500 ml bottle – to be delisted 1 April 2023
- Posaconazole (Posaconazole Juno) tab modified-release 100 mg – new listing and addition of PSS
- Posaconazole (Noxafil) tab modified-release 100 mg – to be delisted 1 April 2023
- Potassium chloride (Span-K) tab long-acting 600 mg (8mmol) – price increase
- Sertraline (Setrona) tab 50 mg and 100 mg – price increase and addition of PSS
- Sodium alginate with sodium bicarbonate and calcium carbonate (Acidex) oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml, 500 ml – price increase
- Sodium hydroxide soln 10% – new listing
- Sunscreen, proprietary (Marine Blue Lotion SPF 50+) lotn, 200 g – price increase and addition of PSS
- Testosterone (Androderm) patch 5 mg per day – price increase
- Tetrabenazine (Motetis) tab 25 mg – price increase and addition of PSS
- Thiamine hydrochloride (Thiamine multichem) tab 50 mg – new listing and addition of PSS
- Thiamine hydrochloride (Max Health) tab 50 mg – to be delisted 1 April 2023

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 November 2022

ALIMENTARY TRACT AND METABOLISM

5	SODIUM ALGINATE WITH SODIUM BICARBONATE AND CALCIUM CARBONATE († price) Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml	7.50	500 ml	Acidex
15	LACTULOSE († price and addition of PSS) Oral liq 10 g per 15 ml – 5% DV Apr-23 to 2025	3.61	500 ml	Laevolac
26	THIAMINE HYDROCHLORIDE (new listing and addition of PSS) Tab 50 mg – 5% DV Apr-23 to 2025	4.65	100	Thiamine multichem
	Note – Max Health tab 50 mg to be delisted from 1 April 2023.			

BLOOD AND BLOOD FORMING ORGANS

42	POTASSIUM CHLORIDE († price) Tab long-acting 600 mg (8 mmol)	15.35	200	Span-K
----	---	-------	-----	--------

CARDIOVASCULAR SYSTEM

49	CHLORTALIDONE [CHLORTHALIDONE] († price and addition of PSS) Tab 25 mg – 5% DV Apr-23 to 2025	6.95	50	Hygroton
----	---	------	----	-----------------

DERMATOLOGICALS

57	CLOTRIMAZOLE († price and addition of PSS) Crm 1% – 5% DV Apr-23 to 2025	1.10	20 g	Clomazol
60	HYDROCORTISONE (new listing and addition of PSS) Crm 1%, 30 g – 5% DV Apr-23 to 2025	1.78	30 g	Ethics
	Note – Hydrocortisone (PSM) crm 1%, 100 g to be delisted from 1 April 2023.			
62	SUNSCREEN, PROPRIETARY († price and addition of PSS) Lotn – 5% DV Apr-23 to 2025	6.50	200 g	Marine Blue Lotion SPF 50+

GENITO-URINARY SYSTEM

64	CLOTRIMAZOLE († price and addition of PSS) Vaginal crm 1% with applicator – 5% DV Apr-23 to 2025	3.50	35 g	Clomazol
	Vaginal crm 2% with applicator – 5% DV Apr-23 to 2025	3.85	20 g	Clomazol

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2022 (continued)

64	INTRA-UTERINE DEVICE (↑ price and addition of PSS) IUD 29.1 mm length × 23.2 mm width – 5% DV Apr-23 to 2025	29.80	1	Choice TT380 Short
	IUD 33.6 mm length × 29.9 mm width – 5% DV Apr-23 to 2025	29.80	1	Choice TT380 Standard
	IUD 35.5 mm length × 19.6 mm width – 5% DV Apr-23 to 2025	33.00	1	Choice Load 375

HORMONE PREPARATIONS

68	TESTOSTERONE (↑ price) Patch 5 mg per day	225.00	30	Androderm
----	--	--------	----	-----------

INFECTIONS

80	CEFALEXIN (↑ price and addition of PSS) Cap 250 mg – 5% DV Apr-23 to 2025	3.85	20	Cephalexin ABM
80	CEFALEXIN (↓ price and addition of PSS) Cap 500 mg – 5% DV Apr-23 to 2025	5.85	20	Cephalexin ABM
80	CEFACLOR (↑ price and addition of PSS) Cap 250 mg – 5% DV Apr-23 to 2025	25.85	100	Ranbaxy-Cefaclor
	Grans for oral liq 25 mg per ml – 5% DV Apr-23 to 2025	3.75	100 ml	Ranbaxy-Cefaclor
80	CEFTRIAXONE (↓ price and addition of PSS) Inj 500 mg vial – 5% DV Apr-23 to 2025	0.79	1	Ceftriaxone-AFT
	Inj 1 g vial – 5% DV Apr-23 to 2025	3.59	5	Ceftriaxone-AFT
87	POSACONAZOLE (new listing and addition of PSS) → Tab modified-release 100 mg – 5% DV Apr-23 to 2025	206.00	24	Posaconazole Juno
	Note – Noxafil tab modified-release 100 mg to be delisted from 1 April 2023.			
88	CASPOFUNGIN (new listing and addition of PSS) → Inj 50 mg vial – 5% DV Apr-23 to 2025	110.00	1	Alchemy Caspofungin
	→ Inj 70 mg vial – 5% DV Apr-23 to 2025	135.00	1	Alchemy Caspofungin
	Note – Max Health inj 50 mg and 70 mg vial to be delisted from 1 April 2023.			
94	DARUNAVIR (new listing) → Tab 600 mg – 1% DV Nov-22 to 2023	196.65	60	Darunavir Viatrix
96	ACICLOVIR (↑ price and addition of PSS) Tab dispersible 400 mg – 5% DV Apr-23 to 2025	5.81	56	Lovir
	Tab dispersible 800 mg – 5% DV Apr-23 to 2025	6.46	35	Lovir

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$ Per		Brand or Generic Manufacturer
--	--	--	-------------------------------------

Changes to Section H Part II – effective 1 November 2022 (continued)

NERVOUS SYSTEM

111	TETRABENAZINE († price and addition of PSS) Tab 25 mg – 5% DV Apr-23 to 2025	106.59	112	Motetis
116	PARACETAMOL (new listing and addition of PSS) Oral liq 250 mg per 5 ml – 20% DV Apr-23 to 2025	3.35	200 ml	Pamol
116	PARACETAMOL (delisting) Oral liq 250 mg per 5 ml	6.25	1,000 ml	Paracare Double Strength
	Oral liq 250 mg per 5 ml - 100 ml bottle Oral liq 250 mg per 5 ml - 200 ml bottle Oral liq 250 mg per 5 ml - 500 ml bottle Note – Paracare Double Strength oral liq 250 mg per 5 ml, oral liq 250 mg per 5 ml – 100 ml, 200 ml and 500 ml bottle to be delisted from 1 April 2023.			
116	CODEINE PHOSPHATE (new listing and addition of PSS) Tab 30 mg – 5% DV Apr-23 to 2025	6.98	100	Noumed
	Tab 60 mg – 5% DV Apr-23 to 2025	13.89	100	Noumed
	Note – PSM tab 30 mg and 60 mg to be delisted from 1 April 2023.			
118	MORPHINE SULPHATE († price and addition of PSS) Cap long-acting 10 mg – 5% DV Apr-23 to 2025	3.00	10	m-Eslon
	Cap long-acting 30 mg – 5% DV Apr-23 to 2025	4.30	10	m-Eslon
	Cap long-acting 60 mg – 5% DV Apr-23 to 2025	9.00	10	m-Eslon
	Cap long-acting 100 mg – 5% DV Apr-23 to 2025	10.50	10	m-Eslon
121	SERTRALINE († price and addition of PSS) Tab 50 mg – 5% DV Apr-23 to 2025	0.99	30	Setrona
	Tab 100 mg – 5% DV Apr-23 to 2025	1.74	30	Setrona
126	LEVOMEPRMAZINE HYDROCHLORIDE (new listing and addition of PSS) Inj 25 mg per ml, 1 ml ampoule – 5% DV Apr-23 to 2025	24.48	10	Wockhardt
	Note – Nozinan inj 25 mg per ml, 1 ml ampoule to be delisted from 1 April 2023.			

	Price (ex man. Excl. GST) \$ Per	Brand or Generic Manufacturer
--	--	-------------------------------------

Changes to Section H Part II – effective 1 November 2022 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

143	OLAPARIB (amended restriction criteria – affected criteria shown only)		
	→ Tab 100 mg.....	3,701.00	56 Lynparza
	→ Tab 150 mg.....	3,701.00	56 Lynparza
	Restricted		
	Initiation – Ovarian cancer		
	Medical oncologist		
	<i>Re-assessment required after 12 months</i>		
	Either:		
	1 Patient is currently on treatment with olaparib and met all remaining criteria (criterion 2) below prior to commencing treatment; or		
	2 All of the following:		
	2-1 Patient has a high-grade serous* epithelial ovarian, fallopian tube, or primary peritoneal cancer; and		
	2-2 There is documentation confirming pathogenic germline BRCA1 or BRCA2 gene mutation; and		
	2-3 Either:		
	2-3.1 All of the following:		
	2-3.1.1 Patient has newly diagnosed, advanced disease; and		
	2-3.1.2 Patient has received one line** of previous treatment with platinum-based chemotherapy; and		
	2-3.1.3 Patient’s disease must have experienced a partial or complete response to the first-line platinum-based regimen; or		
	2-3.2 All of the following:		
	2-3.2.1 Patient has received at least two lines** of previous treatment with platinum-based chemotherapy; and		
	2-3.2.2 Patient has platinum sensitive disease defined as disease progression occurring at least 6 months after the last dose of the penultimate line** of platinum-based chemotherapy; and		
	2-3.2.3 Patient’s disease must have experienced a partial or complete response to treatment with the immediately preceding platinum-based regimen; and		
	2-3.2.4 Patient has not previously received funded olaparib treatment; and		
	2-4 Treatment will be commenced within 12 weeks of the patient’s last dose of the immediately preceding platinum-based regimen; and		
	2-5 Treatment to be administered as maintenance treatment; and		
	2-6 Treatment not to be administered in combination with other chemotherapy.		

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 November 2022 (continued)

220	DURVALUMAB (amended restriction criteria – affected criteria shown only)			
	→ Inj 50 mg per ml, 10 ml vial	4,700.00	1	Imfinzi
	→ Inj 50 mg per ml, 2.4 ml vial	1,128.00	1	Imfinzi
	Restricted			
	Initiation – Non-small cell lung cancer			
	Medical oncologist			
	<i>Re-assessment required after 3 months</i>			
	Either:			
	1 Patient is currently on treatment with durvalumab and met all remaining criteria (criterion 2) below prior to commencing treatment; or			
	2 All of the following:			
	2-1 Patient has histologically or cytologically documented stage III, locally advanced, unresectable non-small cell lung cancer (NSCLC); and			
	2-2 Patient has received two or more cycles of platinum-based chemotherapy concurrently with definitive radiation therapy; and			
	2-3 Patient has no disease progression following the second or subsequent cycle of platinum-based chemotherapy with definitive radiation therapy treatment; and			
	2-4 Patient has a ECOG performance status of 0 or 1; and			
	2-5 Patient has completed last radiation dose within 8 weeks of starting treatment with durvalumab; and			
	2-6 Patient must not have received prior PD-1 or PD-L1 inhibitor therapy for this condition; and			
	2-7 Either:			
	2-7.1 Durvalumab is to be used at a maximum dose of no greater than 10 mg/kg every 2 weeks; or			
	2-7.2 Durvalumab is to be used at a flat dose of 1500 mg every 4 weeks; and			
	2-8 Treatment with durvalumab to cease upon signs of disease progression.			
224	AZATHIOPRINE (1 price and addition of PSS)			
	Tab 25 mg – 5% DV Apr-23 to 2025	7.36	60	Azamun

VARIOUS

249	SODIUM HYDROXIDE (new listing)			
	Soln 10%			

SPECIAL FOODS

269	PAEDIATRIC ENTERAL FEED 1 KCAL/ML (amended presentation description)			
	→ Liquid 2- 82.7 g protein, 12.3 g carbohydrate and 4.4 g fat per 100 ml, 500 ml bottle			<i>e.g. Nutrini RTH</i>
270	HIGH PROTEIN ORAL FEED 2.4 KCAL/ML (delisting delayed)			
	Only to be used for patients currently on or would be using Fortisip or Fortisip Multi Fibre			
	→ Liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle			<i>e.g. Fortisip Compact Protein</i>
	Note – e.g. Fortisip Compact Protein liquid 14.6 g protein, 25.3 g carbohydrate and 9.6 g fat per 100 ml, 125 ml bottle delisting delayed to 1 December 2023.			

Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 October 2022

NERVOUS SYSTEM

120	CITALOPRAM HYDROBROMIDE (new listing and addition of PSS) Tab 20 mg – 5% DV Mar-23 to 2025 2.86 Note – PSM Citalopram tab 20 mg to be delisted from 1 March 2023.	84	Celapram
-----	--	----	-----------------

Index

Pharmaceuticals and brands

A

Aciclovir	6
Acidex	5
Alchemy Caspofungin	6
Androderm.....	6
Azamun	9
Azathioprine	9

C

Caspofungin.....	6
Cefaclor.....	6
Cefalexin.....	6
Ceftriaxone.....	6
Ceftriaxone-AFT	6
Celapram	10
Cephalexin ABM.....	6
Chlorthalidone [Chlorthalidone]	5
Chlorthalidone.....	5
Choice Load 375.....	6
Choice TT380 Short.....	6
Choice TT380 Standard.....	6
Citalopram hydrobromide	10
Clomazol.....	5
Clotrimazole.....	5
Codeine phosphate	7

D

Darunavir	6
Darunavir Viatrix.....	6
Durvalumab	9

F

Fortisip Compact Protein	9
--------------------------------	---

H

High protein oral feed 2.4 kcal/ml	9
Hydrocortisone	5
Hygroton.....	5

I

Imfinzi.....	9
Intra-uterine device.....	6

L

Lactulose.....	5
Laevolac	5
Levomepromazine hydrochloride	7
Lovir.....	6
Lynparza.....	8

M

Marine Blue Lotion SPF 50+	5
m-Eslon.....	7
Morphine sulphate.....	7
Motetis	7

N

Nutrini RTH.....	9
------------------	---

O

Olaparib	8
----------------	---

P

Paediatric enteral feed 1 kcal/ml	9
Pamol.....	7
Paracare Double Strength.....	7
Paracetamol.....	7
Posaconazole	6
Posaconazole Juno	6
Potassium chloride	5

R

Ranbaxy-Cefaclor.....	6
-----------------------	---

S

Sertraline	7
Setrona.....	7
Sodium alginate with sodium bicarbonate and calcium carbonate	5
Sodium hydroxide	9
Span-K	5
Sunscreen, proprietary	5

T

Testosterone	6
Tetrabenazine.....	7
Thiamine hydrochloride	5
Thiamine multichem.....	5

Pharmaceutical Management Agency
Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand
Phone: 64 4 460 4990 - www.pharmac.govt.nz
Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa [New Zealand Government](#)

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

